Related references
Note: Only part of the references are listed.Therapeutic targets in myeloma bone disease
Silvia Marino et al.
BRITISH JOURNAL OF PHARMACOLOGY (2021)
Collagenated Porcine Heterologous Bone Grafts: Histomorphometric Evaluation of Bone Formation Using Different Physical Forms in a Rabbit Cancellous Bone Model
Rui I. Falacho et al.
MOLECULES (2021)
Ubiquitin-specific protease 53 promotes osteogenic differentiation of human bone marrow-derived mesenchymal stem cells
Dawoon Baek et al.
CELL DEATH & DISEASE (2021)
From Stem Cells to Bone-Forming Cells
Samantha Donsante et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Targeting Bortezomib to Bone Increases Its Bone Anabolic Activity and Reduces Systemic Adverse Effects in Mice
Hua Wang et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Silpa Narayanan et al.
DRUG RESISTANCE UPDATES (2020)
Ixazomib Improves Bone Remodeling and Counteracts Sonic Hedgehog Signaling Inhibition Mediated by Myeloma Cells
Daniele Tibullo et al.
CANCERS (2020)
Destroy to Rebuild: The Connection Between Bone Tissue Remodeling and Matrix Metalloproteinases
Eugenio Hardy et al.
FRONTIERS IN PHYSIOLOGY (2020)
Adjuvant Drug-Assisted Bone Healing: Advances and Challenges in Drug Delivery Approaches
Rebecca Rothe et al.
PHARMACEUTICS (2020)
Cell cycle exit during bortezomib-induced osteogenic differentiation of mesenchymal stem cells was mediated by Xbp1s-upregulated p21Cip1and p27Kip1
Dan Zhang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Targeting anti-cancer agents to bone using bisphosphonates
Lianping Xing et al.
BONE (2020)
Phosphorylation-dependent osterix degradation negatively regulates osteoblast differentiation
Seira Hoshikawa et al.
FASEB JOURNAL (2020)
ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation
Dan Zhang et al.
STEM CELL RESEARCH & THERAPY (2020)
Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma
Xavier Leleu et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Anabolic Therapies in Osteoporosis and Bone Regeneration
Gabriele Russow et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation-induced osteoporosis
Abhishek Chandra et al.
FASEB JOURNAL (2018)
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America
Noopur Raje et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
The bone remodelling cycle
J. S. Kenkre et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2018)
Cancer Metastases to Bone: Concepts, Mechanisms, and Interactions with Bone Osteoblasts
Alison B. Shupp et al.
CANCERS (2018)
Ixazomib: a novel drug for multiple myeloma
Saurabh Zanwar et al.
EXPERT REVIEW OF HEMATOLOGY (2018)
Bone-Fracture-Targeted Dasatinib-Oligoaspartic Acid Conjugate Potently Accelerates Fracture Repair
Mingding Wang et al.
BIOCONJUGATE CHEMISTRY (2018)
Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy
Denise Toscani et al.
FRONTIERS IN IMMUNOLOGY (2018)
The Proteasome and Myeloma-Associated Bone Disease
Fabrizio Accardi et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
Ixazomib enhances parathyroid hormone-induced β-catenin/T-cell factor signaling by dissociating β-catenin from the parathyroid hormone receptor
Yanmei Yang et al.
MOLECULAR BIOLOGY OF THE CELL (2017)
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors
Denise Toscani et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
E11/Podoplanin Protein Stabilization Through Inhibition of the Proteasome Promotes Osteocyte Differentiation in Murine in Vitro Models
Katherine A. Staines et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2016)
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20
B. Dalla Palma et al.
LEUKEMIA (2016)
A novel nonviral gene delivery tool of BMP-2 for the reconstitution of critical-size bone defects in rats
Andreas Kolk et al.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A (2016)
Cbl-b and c-Cbl negatively regulate osteoblast differentiation by enhancing ubiquitination and degradation of Osterix
You Hee Choi et al.
BONE (2015)
Local Application of a Proteasome Inhibitor Enhances Fracture Healing in Rats
Toshitaka Yoshii et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2015)
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
Fabrizio Accardi et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease
Antonio Garcia-Gomez et al.
CLINICAL CANCER RESEARCH (2014)
Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2
Zhiyu Wang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma
R. Silbermann et al.
LEUKEMIA (2014)
Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro
Yali Li et al.
LEUKEMIA RESEARCH (2014)
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
David Siegel et al.
HAEMATOLOGICA (2013)
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
M. A. Hurchla et al.
LEUKEMIA (2013)
Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma
Bo Hu et al.
PLOS ONE (2013)
Myeloma bone disease: Pathophysiology and management
Rebecca Silbermann et al.
JOURNAL OF BONE ONCOLOGY (2013)
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Ravi Vij et al.
BLOOD (2012)
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy
Evangelos Terpos et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Effects of Bone-Targeted Agents on Cancer Progression and Mortality
Robert Coleman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies
Edmund C. Lee et al.
CLINICAL CANCER RESEARCH (2011)
In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
Dharminder Chauhan et al.
CLINICAL CANCER RESEARCH (2011)
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients
Maurizio Zangari et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients
Maurizio Zangari et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
A Proteasome Inhibitor, Bortezomib, Inhibits Breast Cancer Growth and Reduces Osteolysis by Downregulating Metastatic Genes
Marci D. Jones et al.
CLINICAL CANCER RESEARCH (2010)
Cellular and Molecular Mechanisms of Bone Remodeling
Liza J. Raggatt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
Angela Pennisi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts
Robert L. Jilka et al.
BONE (2009)
Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma
Sarah Deleu et al.
CANCER RESEARCH (2009)
The proteasome: Overview of structure and functions
Keiji Tanaka
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2009)
Proteasome inhibitors in cancer therapy: Lessons from the first decade
Robert Z. Orlowski et al.
CLINICAL CANCER RESEARCH (2008)
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo
Claire M. Edwards et al.
BLOOD (2008)
Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts
Xin Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Stimulation of new bone formation by the proteasome inhibitor, bortezomib:: implications for myeloma bone disease
Babatunde O. Oyajobi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Deborah J. Kuhn et al.
BLOOD (2007)
Production of Wnt inhibitors by myeloma cells: Potential effects on canonical Wnt pathway in the bone microenvironment
Nicola Giuliani et al.
CANCER RESEARCH (2007)
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients
Nicola Giuliani et al.
BLOOD (2007)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma
Therese Standal et al.
BLOOD (2007)
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition
Silke Meister et al.
CANCER RESEARCH (2007)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Regulation of adult bone mass by the zinc finger adapter protein Schnurri-3
Dallas C. Jones et al.
SCIENCE (2006)
Ubiquitin ligases: cell-cycle control and cancer
KI Nakayama et al.
NATURE REVIEWS CANCER (2006)
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
M Groll et al.
STRUCTURE (2006)
Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases
PG Whang et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2005)
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2
T Oshima et al.
BLOOD (2005)
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
M Zangari et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation
N Giuliani et al.
BLOOD (2005)
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells
JZ Qin et al.
CANCER RESEARCH (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib
CR Berkers et al.
NATURE METHODS (2005)
Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation
M Yamashita et al.
CELL (2005)
Mechanisms of disease: Mechanisms of bone metastasis
GD Roodman
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo
M Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells
JW Lee et al.
BLOOD (2004)
Marrow stromal cells and osteoclast precursors differentially contribute to TNF-α-induced osteoclastogenesis in vivo
H Kitaura et al.
JOURNAL OF IMMUNOLOGY (2004)
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
E Tian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts - A putative explanation for why intermittent administration is needed for bone anabolism
T Bellido et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma:: proposal for a novel prognostic index
E Terpos et al.
BLOOD (2003)
E3 ubiquitin ligase Smurf1 mediates core-binding factor α1/Runx2 degradation and plays a specific role in osteoblast differentiation
M Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
NF-κB as a therapeutic target in cancer
RZ Orlowski et al.
TRENDS IN MOLECULAR MEDICINE (2002)
Metastasis to bone: Causes, consequences and therapeutic opportunities
GR Mundy
NATURE REVIEWS CANCER (2002)
The bone lining cell: Its role in cleaning Howship's lacunae and initiating bone formation
V Everts et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment
N Giuliani et al.
BLOOD (2001)
Share Paper
